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Abstract
Background: The PRECISE (PREgnancy Care Integrating translational Science, Everywhere) Network is a new and
broadly-based group of research scientists and health advocates based in the UK, Africa and North America.
Methods: This paper describes the protocol that underpins the clinical research activity of the Network, so that the
investigators, and broader global health community, can have access to ‘deep phenotyping’ (social determinants of
health, demographic and clinical parameters, placental biology and agnostic discovery biology) of women as they
advance through pregnancy to the end of the puerperium, whether those pregnancies have normal outcomes or
are complicated by one/more of the placental disorders of pregnancy (pregnancy hypertension, fetal growth
restriction and stillbirth). Our clinical sites are in The Gambia (Farafenni), Kenya (Kilifi County), and Mozambique
(Maputo Province). In each country, 50 non-pregnant women of reproductive age will be recruited each month for
1 year, to provide a final national sample size of 600; these women will provide culturally-, ethnically-, seasonally-
and spatially-relevant control data with which to compare women with normal and complicated pregnancies.
Between the three countries we will recruit ≈10,000 unselected pregnant women over 2 years. An estimated 1500
women will experience one/more placental complications over the same epoch. Importantly, as we will have
accurate gestational age dating using the TraCer device, we will be able to discriminate between fetal growth
restriction and preterm birth. Recruitment and follow-up will be primarily facility-based and will include women
booking for antenatal care, subsequent visits in the third trimester, at time-of-disease, when relevant, during/
immediately after birth and 6 weeks after birth.
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Conclusions: To accelerate progress towards the women’s and children’s health-relevant Sustainable Development
Goals, we need to understand how a variety of social, chronic disease, biomarker and pregnancy-specific
determinants health interact to result in either a resilient or a compromised pregnancy for either mother or fetus/
newborn, or both. This protocol has been designed to create such a depth of understanding. We are seeking
funding to maintain the cohort to better understand the implications of pregnancy complications for both
maternal and child health.
Keywords: Pregnancy, Africa south of the Sahara, Biorepository, Pre-eclampsia, Biological specimens,
Background
The PRECISE Network is a new and broadly-based group
of research scientists and health advocates mainly based in
the UK and Africa. With core funding from the UK Re-
search and Innovation (UKRI), we are establishing this
network through a shared project investigating three im-
portant placental complications of pregnancy: high blood
pressure (pregnancy hypertension), fetal growth restriction
(FGR) and stillbirth. We estimate that about 46,000
women and two-and-a-half million babies (both before
and after birth) die due to these problems every year, half
of them in Africa [1]. In addition, about 50 million women
and babies will have their short and long-term health al-
tered because of these complications. These numbers rep-
resent one of the great global inequalities of our time.
The co-investigator network has been established to
deliver scientific excellence across the PRECISE objec-
tives and broad programme of holistic, interdisciplinary
pregnancy research. Figure 1 and the Network member-
ship list (see Acknowledgements) show the global geog-
raphy of institutions collaborating in this network. Our
clinical activity is focused on West (The Gambia), East
(Kenya) and South (Mozambique) sub-Saharan Africa.
This protocol paper is complemented by specific data-
base and biorepository papers that provide detail related
to data and sample collection methods, processing, mon-
itoring and planned analyses.
Aims and objectives of PRECISE
The broad objectives for The PRECISE Network cover
all strategic areas of the programme: research capacity
building, global maternal and child health research, part-
nership building and advocacy.
1. Build individual and institutional research capacity
across Africa and the UK through a shared
pregnancy research programme of work.
2. Develop a unique cohort of biologically and
contextually characterised pregnant and non-
pregnant women of reproductive age in East
(Kenya), West (The Gambia) and Southern
(Mozambique) sub Saharan Africa to support re-
search into placental disorders (hypertension, fetal
growth restriction and stillbirth) in the region.
3. Build sustainable, equitable partnerships across the
individuals and institutions in The PRECISE
Network, ensuring leadership and autonomy in
research strategy and delivery across the
collaborators.
Fig. 1 The geography of PRECISE. blue = active clinical sites; grey =methodology & co-ordination sites. MMR, maternal mortality ratio; NMR,
neonatal mortality rate; SBR, stillbirth rate; U5MR, under-5 mortality rate
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4. Embed PRECISE in the global maternal and child
health landscape across the areas of research, health
service providers, NGOs, industry and national and
international policy to maximise the contribution of
PRECISE to the attainment of SDG 3 through
broad advocacy and engagement.
The research outcomes planned within objective 2 (as
above) are detailed as follows:
2.a To develop a unique cohort of pregnancies affected
by placental disease and assess the prevalence of
these disorders in women attending antenatal care
in centres representative of urban and rural
communities in three sub-Saharan African
countries.
2.b To develop cohorts of women with unselected
pregnancies and non-pregnant women of repro-
ductive age, for comparison. These cohorts will pro-
vide appropriate data with which to compare the
context of women and their biology as they have
pregnancies complicated by placental disorders, or
not. Sufficient culturally and geographically relevant
data do not exist to identify pathways to pregnancy
resilience or vulnerability, considering women’s bur-
den of infectious and/or non-communicable disease.
Existing control data have been almost uniformly
from more-developed countries in Europe, North
America and Australasia.
2.c To investigate environmental, biological,
epidemiological, clinical, social/cultural and health
system factors affecting the ability to understand,
prevent and manage the effects of placental diseases
for African women and their families.
2.d To investigate the potential for introduction of
novel methods to assist the prevention, diagnosis
and management of placental disorders in sub-
Saharan Africa. Such methods could be new diag-
nostics based on the agnostic proteomic screening
of samples from women with or without pregnancy
complications. New pathways to disease may be
identified that could be circumvented with novel
therapeutics. In addition, the role of culturally and
geographically relevant interventions (e.g. faith-
based discussions around women’s autonomy of
decision-making or the provision of roads and brid-
ges to optimise access to health care) may be
emphasised as critical health interventions.
Methods
Study design
This phase of the planned PRECISE initiative is a pro-
spective observational cohort design. Where health issues
are identified for individual women and newborns, then
they will be referred into existing health system pathways.
The funding mechanism for this cohort study specifically
precluded clinical trials, enforcing the purely observational
design. Once biomarker data become available for women
after the clinical phase is completed, important clinical
data (e.g., hyperglycaemia) will be provided to women and
their caregivers. We are seeking further funding to begin
intervention studies for pregnant and puerperal women,
and their offspring, in these communities (e.g., stepped-
wedge cluster randomised controlled trials).
Research settings
The PRECISE sites have been chosen in locations with re-
search excellence and where data collection will produce
representative cohorts of West, East and Southern African
women. Given the transition towards increasingly urban
populations in Africa and elsewhere in less-developed
countries, PRECISE has been designed to recruit women
living in both urban and rural settings in the three geog-
raphies (Figs. 2, 3 and 4).
Specific variations on protocol implementation were
made to respond to individual country scientific and eth-
ical review boards’ recommendations.
To maximise the quality of the biorepositories, each
country’s selection of sites was undertaken to ensure
rapid access to definitive biorepository facilities.
The Gambia (Fig. 2)
Our primary partner in The Gambia is the MRC Unit The
Gambia at LSHTM. The field research will occur at the
Farafenni Hospital (urban hospital) and associated rural
primary health centres (PHCs) in Illiasa and Ngayen San-
jal; these health facilities cover a population under demo-
graphic surveillance since the 1980s.
Kenya (Fig. 3)
Our primary partner in Kenya is the Aga Khan Univer-
sity (East Africa) (AKU). The field research will be con-
ducted through the Mombasa field station, with field
activity in Mariakani Subcounty Hospital (urban) and
Rabai Health Centre (rural).
Mozambique (Fig. 4)
Our primary partner in Mozambique is the Centro de
Investigação de Saúde de Manhiça (CISM). The field re-
search will occur in the Manhiça District Hospital (pri-
marily urban population) and Xinavane Rural Hospital
(primarily rural population), with some laboratory activ-
ity at Eduardo Mondlane University, Physiological Sci-
ence and Pathology Departments in Maputo.
The research participants
While PRECISE is designed to answer specific research
questions, a major legacy will be the highly-phenotyped
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representative cohorts of West, East and Southern African
women and the creation of an incomparable Africa-based
biorepository for future hypothesis-generated and generat-
ing research. The core activity will be to collect environ-
mental, social, geographical, demographic, clinical and
biological data related to three populations of women.
Specific details of the planned cohorts are provided
below.
Research processes
Community engagement
The PRECISE Network clinical sites have been working
in these communities for many years and have built
strong relationships of trust with their communities.
The local PRECISE leadership and study teams have in-
formed participating communities of the study and, par-
ticularly, had in-depth discussions on the best approach
Fig. 3 Kenyan sites
Fig. 2 Gambian sites
von Dadelszen et al. Reproductive Health 2020, 17(Suppl 1):51 Page 4 of 15
within a given community for the collection of samples
that may have cultural or religious significance such as
maternal blood, cord blood and placental samples. In
addition, the team has discussed with communities the
best approach for collecting specimens immediately fol-
lowing childbirth (cord blood and placental tissue) and
will return the placenta to the family (if that is their
wish) after it is weighed and photographed, and small
samples are taken from it.
Community engagement activities will be conducted
in all study sites to ensure the women and communities
in which they live are aware of the PRECISE programme
of work. A brief overview of planned activity is presented
in Table 1.
Consent process
Women enrolled in the PRECISE study will have an op-
portunity to read or be read the informed consent in
their native language and to ask any questions they may
have. Consent will be confirmed with the participant’s
signature or a thumbprint. In the absence of a signature,
a witness (other than the member of the research team
obtaining consent) will be asked to sign. Finally, the
member of the research team obtaining consent will sign
the form. For recruitment of women aged 14 - 17 years
old, the consent and assent processes will be guided by
in-country ethics boards.
We will request tiered consent, whereby women will
be asked to provide general consent, as well as specific
vaginal swab consent, genetic study consent, the sharing
of samples between African sites, the sharing of data and
samples beyond Africa, and the sharing of data and
samples with industry. It is specified that samples are
only being taken for research purposes and will have no
impact on their clinical care. The informed consent doc-
uments permit future research related to pregnancy and
birth and their complications.
Vulnerable populations
This study involves pregnant women and newborns. In
most sites, potential participants do not speak English.
In these sites, consent will be taken in the local language
to ensure that the potential participant understands the
research. Every effort will be made to ensure their volun-
tary participation. It will be explained that participation
is voluntary and can be terminated at any time without
reason and without any penalty. If the potential partici-
pant has any questions, they will be answered in their
native language to ensure that they understand the re-
search and their potential role in it.
Confidentiality
To ensure privacy, consenting will take place in a private
room at the local health facilities. Hard copies of any
study-related forms, e.g. patient logs, will be stored in a
locked cabinet in a storage room under supervision of
the principal investigators (and destroyed after entering
the database and performing the relevant quality control
checks performed through the monthly data monitoring
reports). Electronic records will be stored in password-
protected computers and tablets and only approved
study personnel will have access to entire level of infor-
mation (e.g. laboratory technicians will have access only
to a subset of data, thus reducing the risk for a major
Fig. 4 Mozambican sites
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level breach). Access to the entire dataset will be re-
stricted to the main PI and the site PIs, to keep a strict
control of the data. All specimens and associated pheno-
typic data will be de-identified and given a unique par-
ticipant identifier code and no personal information will
be stored in the data management systems.
General points related to data collection
As described, the PRECISE research programme will col-
lect 360° data that place women in their social, geo-
graphic, health services, nutritional and chronic disease
contexts, as well as collecting important biophysical and
biomarker data that will explain risks for, and pathways
to, placental disorders and other complications of preg-
nancy. Details of the data fields being collected are in
the complementary database paper [2].
Using mixed methods, we will assess women in terms
of their beliefs and practices around pregnancy, access
to care and the acceptability of novel diagnostic tools
and interventions. Similarly, we will assess these factors
in men’s groups, mothers and mothers-in-law, faith and
community leaders, and health service providers and ad-
ministrators. Much of this work has already been
completed in Mozambique during the CLIP trial feasibil-
ity study [3–6]. This activity will be supplemented in
Mozambique and replicated in The Gambia and Kenya.
Additional details are provided in the qualitative
methods paper [7].
Non-clinical data will relate to their nutritional status,
demographics and women’s natural and built environ-
ment, this includes data on the women’s home including
the structure, building materials, proximity to a toilet as
well as the environment including cooking facilities and
water availability. In addition, we will capture data on
available health services (and an assessment of the qual-
ity of care provided by them). All data will be entered
into the PRECISE data platform. These data will largely
be collected during the enrolment visit for all women,
whether non-pregnant or pregnant.
Clinical data will be collected using an electronic data
collection platform with the additional PRECISE data
fields. At enrolment, these data will include limited in-
formation about past obstetric, medical, and surgical his-
tory for all women. For pregnant women, best estimates
of pregnancy dating will be obtained at the first visit. At
all visits, women will have their weight, blood pressure
Table 1 Community engagement
The Gambia Mozambique Kenya
Stakeholders to
be engaged
Faith leaders
Non-religious community
leaders
Women
attending antenatal clinic (ANC)
Community leaders
Pregnant women
Women of reproductive age
Mothers and mothers-in-law
Partners
Stakeholders (Ethical committees,
investigators, policy makers)
Nurses
Health care workers
Community leaders
Community health volunteers
(CHV)
Community-wide meetings
Pregnant women, partners, family
members
Methods of
engagement
Go out into the community
to engage with community leaders
Open days at health facilities
to explain to the women attending ANC
Health talks in the health facility
Community meetings
Informal conversations
Discussion boards
Health talks (baraza) or videos
on loop at ANC
Community meetings (this will
tag on to existing community-
based meetings)
Additional community meetings
may be convened for target
audiences (pregnant women,
mothers, other in-laws, partners)
Key messages Introduction to research
Introduction to informed consent
When/how/why storing biological
samples
Assess the acceptability of the biorepository
Promote early disclose of pregnancy and early
attendance to the ANC visits.
Promote birth preparedness and hospital delivery
Identification of a health unit to give birth in
Identification of skilled birth attendants
Introduction to research
Introduction to informed
consent
When/how/why storing
biological samples
Frequency of
engagement
Sensitisation activities will occur before
recruitment starts and continue during the
recruitment period
At the end of the study, we will communicate
the results to the community following
the same procedures
Health talks will be conducted twice a
week during the morning with
pregnant women in the health facility
In the community meetings with specific groups
will be conducted
One meeting per month with the stakeholders
Initiate activities 2 months before
data collection.
Activities will be heightened in
communities closest to the
health facilities as they will have
the largest number of women
from these areas
Activities will occur throughout
the study. Each community will
be approached roughly once
per month
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(BP) and SpO2 measured. Full details on the data being
captured are outlined in the database paper [2].
Specific clinical tools to be tested and validated
within PRECISE include: (i) the TraCer (transcere-
bellar diameter) app that will date all pregnancies
using the highly-conserved and growth restriction-
resistant transcerebellar diameter (separate in-
country, sub-project-specific ethics approval for the
development and utility testing of the app has been
granted) (pregnancy only); (ii) the CRADLE VSA
semi-automated and validated BP device will be used
for all clinical measurements of blood pressure (BP)
in the study [8–14] (non-pregnancy and pregnancy);
(iii) pulse oximetry will be used to assess the impact
of cardiorespiratory disease [15–21] (non-pregnancy,
pregnancy and neonates); (iv) the PIERS On the
Move (POM) platform to provide time-of-disease
risk estimates to hypertensive pregnant women using
the PIERS (Pre-eclampsia Integrated Estimate of
RiSk) models [15, 22–35] (non-pregnancy and preg-
nancy); and, possibly, (v) WOICE, the WHO Mater-
nal Morbidity Working Group Tool [36–39] at visits
in the third trimester.
Standards for the use of the CRADLE BP device, pulse
oximetry and TraCer platform will be detailed in the
relevant portions of the clinical SOP.
General points about consent
In all countries, women aged 18 years old or older can
provide informed consent for research, and pregnant
women aged 16 and 17 years old can provide informed
consent. In Mozambique, pregnant women aged 14 and
15 years old can provide assent for research with consent
provided by a custodial adult. The Department of Health
in Kilifi Country has asked us to replicate this in their
jurisdiction, and the required ethical amendments are in
progress. For all cohorts, we have set an upper age limit
at 49 years of age. We will exclude any women who have
already been approached and declined participation in
PRECISE.
Cohort 1: non-pregnant women of reproductive age (Fig. 5)
In each country, 50 women will be recruited each month
for 1 year, to provide a total national sample size of 600
non-pregnant women of reproductive age. These women
will provide culturally, ethnically and spatially-relevant
control data with which to compare women with normal
and complicated pregnancies (PRECISE Objective 2b).
Recruitment will occur throughout the year to provide
seasonal data, with the associated fluctuations in geo-
graphical (due to seasonal migration) and infectious dis-
ease burdens of risk.
Cohort 1: inclusion criteria
 Attending facility for the care of someone else (e.g.
infant vaccinations) or their own care (family
planning assessment) or in the community (using
the DHS infrastructure).
 Not pregnant by self-report (confirmed by a preg-
nancy test) or within the last 6 months by self-
report (including miscarriage, termination, stillbirth
or live birth).
These women will be approached either in the commu-
nity (in The Gambia) or when attending the facility for the
care of someone else (e.g. for infant vaccinations) or for
their own care (family planning assessment) (Mozambique
and Kenya), and asked to provide data and samples at a
single time point. Non-clinical and clinical data as well as
biological samples will be collected during the first year of
the clinical phase of the project.
At the encounter, consenting women will be asked to
provide:
 Demographic, non-clinical and clinical data.
 Blood, urine and vaginal swabs.
Fig. 5 Flow and sampling of nonpregnant women of
reproductive age
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Cohort 2: unselected pregnant women (Fig. 6)
We are aiming for approximately 10,000 women to be
recruited to this cohort across the three countries. These
women will be approached when visiting the clinic for
antenatal care and will be asked to provide data and bio-
logical samples to derive normative ranges for pregnant
women in less-developed countries (PRECISE Objective
2b). We will recruit women age 14*- 49 years-old (*as
pregnant adolescents are at increased risk of placental
disease) [40]. For recruitment of women aged 14 - 17
years old we will be guided by the consent and assent
processes advised by in-country ethics boards. Research
partners in the study countries have advised that preg-
nant women aged 16 years and over will not require par-
ental consent to participate but can provide consent
themselves.
Cohort 2: inclusion criteria
 Pregnant and attending facility for their own care or
for the care of someone else.
 Have not been referred from another facility.
Cohort 2: exclusion criteria
 Does not plan to deliver at this facility.
Study recruitment (first study visit)
It is anticipated that the median gestational age at book-
ing in each country will be about 24–27 weeks of preg-
nancy (unpublished data from the Community-Level
Interventions for Pre-eclampsia [CLIP] trials).
Whenever possible, at the booking visit women will be
approached for participation. Consenting women will
have their pregnancies dated using, in order of accuracy,
ultrasound dating (recognised to be very uncommon in
these settings), certain last menstrual period, estimated
last menstrual period and symphysis-fundal height (sup-
plemented, for study purposes, by the ultrasound-based
transcerebellar diameter (TraCer) device that determines
gestational age using the highly-conserved transcerebel-
lar diameter [41]); the TraCer dating will be used as the
gold standard for the academic enterprise. As the
TraCer device does not yet have a CE mark it is not ap-
propriate that these data be used to direct clinical care;
however, if during the scan there are concerns about the
fetus or pregnancy, the women will be referred down the
standard clinical care pathway for further investigation.
If TraCer is CE marked during the clinical phase of PRE-
CISE, these data will then begin being shared with clin-
ical teams. Thereafter, the women will be asked to
provide:
 Baseline demographic, non-clinical and clinical data.
 Blood, urine and vaginal swab.
Should a woman not be identified and recruited at her
booking visit (and not declined participation), she will be
approached at her next visit and, if informed consent is
obtained, she will be recruited into PRECISE and the
above-described data and samples obtained.
Third trimester
Between 28 weeks’ gestation and the onset of labour,
and at least 4 weeks after the study recruitment visit,
participating pregnant women will be asked to provide:
 Non-clinical and clinical data, including
administration of the WHO maternal morbidity
working group ANC tool [42].
 Blood and urine.
Fig. 6 Flow and sampling of unselected pregnant women
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Intrapartum, the following will be collected:
 An intrapartum vaginal swab will be taken in
association with a routine, clinically-indicated vagi-
nal examination.
Immediately postpartum
Participating women will be asked to provide:
 Non-clinical and clinical data.
 Placental samples and cord blood.
Within 48 h postpartum
Prior to discharge home, and up to 48 h postpartum,
participating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
In addition, permission will be requested to gather the
following neonatal data and samples:
 Clinical data.
 Neonatal heel prick (if no cord blood sample
collected).
Six weeks postpartum
At, or soon as possible after, 6 weeks postpartum, par-
ticipating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
In addition, permission will be requested to gather the
following neonatal data and samples:
 Non-clinical and clinical data.
 Neonatal stool sample (Kenya only)
Cohort 3 & 4: pregnant women at time-of-disease (Fig. 7)
Cohort 3 will include women who have pregnancies
complicated by pregnancy hypertension (systolic blood
pressure ≥ 140mmHg or diastolic blood pressure ≥ 90
mmHg) or FGR (as suspected by the clinician undertak-
ing their care). Cohort 4 includes women with who are
either experiencing an intrauterine fetal death or who
have delivered a stillborn infant. These women will be
approached when visiting the clinic for antenatal care or
if they have been referred for care due to suspected or
diagnosed placental complications. We will recruit
women age 14*-49 (*as pregnant adolescents are at high
risk of placental disease). Research partners in the study
countries have advised that pregnant women aged 16
and over will not require parental consent to participate
but can provide consent themselves.
Cohort 3: inclusion criteria
 Pregnant and attending facility for their own care.
 Can have been referred from another facility.
 By clinical assessment, have hypertension or
suspected FGR (without hypertension)
Cohort 4: inclusion criteria
 Pregnant and attending facility for their own care.
 Can have been referred from another facility.
 By clinical assessment, have intrauterine fetal death
(IUFD) or stillbirth.
Fig. 7 Flow and sampling of pregnant women with suspected/confirmed placental disease
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Time-of-disease – cohorts 3 & 4
With the first diagnosis of pregnancy hypertension ≥20+ 0
weeks, clinical suspicion of fetal growth restriction, or fetal
death in utero, women will be approached for recruitment
and consent. Health workers will be trained in appropriate
and sensitive recruitment of women in the time-of-disease
cohort, acknowledging the emotional distress that women
may be feeling at this time. Consenting pregnant women
will be asked to provide:
 Non-clinical and clinical data.
 Blood, urine and vaginal swab.
Third trimester
Between 28 weeks’ gestation and the onset of labour,
and at least four weeks after the study recruitment visit,
participating pregnant women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
Intrapartum, the following will be collected:
 An intrapartum vaginal swab will be taken in
association with a routine, clinically-indicated vagi-
nal examination.
Immediately postpartum
Participating women will be asked to provide:
 Non-clinical and clinical data.
 A placental sample and cord blood.
Cohort 3 only - within 48 h postpartum
Prior to discharge home, and up to 48 h postpartum,
participating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
In addition, permission will be requested to gather the
following neonatal data and samples:
 Clinical data.
 Neonatal heel prick (if no cord blood sample
collected).
Cohort 4 only - within 48 h postpartum
Prior to discharge home, and up to 48 h postpartum,
participating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
In addition, permission will be requested to gather the
following fetal/neonatal data:
 Clinical data.
Cohort 3 only - six weeks postpartum
At, or soon as possible after, 6 weeks postpartum, par-
ticipating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
In addition, permission will be requested to gather the
following neonatal data and samples:
 Non-clinical and clinical data.
 Neonatal stool sample (Kenya only)
Fig. 8 Flow and sampling of women with stillbirths recruited postpartum
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Cohort 4 only –six weeks postpartum
At, or soon as possible after, 6 weeks postpartum, par-
ticipating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
Cohort 5: women with stillbirths recruited postpartum (Fig.
8) (Kenya only)
For women who have been referred to the facility with
IUFD and for whom it will not be possible or appropriate
to approach and consent before delivery, consent to col-
lect retrospective data and samples will be sought postpar-
tum. We will recruit women age 14*-49 (*as pregnant
adolescents are at high risk of placental disease) in the de-
livery suites of the PRECISE facilities. As for Cohorts 3 &
4, for recruitment of women aged 14 - 17 years old we will
be guided by the consent and assent processes advised by
in-country ethics boards. Research partners in the study
countries have advised that pregnant women aged 16 and
over will not require parental consent to participate but
can provide consent themselves.
Cohort 5: inclusion criteria
 Referred to facility with IUFD or recently delivered a
stillborn baby.
Immediately postpartum
Participating women will be asked to provide:
 A placental sample and cord blood.
Within 48 h postpartum
Prior to discharge home, and up to 48 h postpartum,
participating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
Six weeks postpartum
At, or soon as possible after, 6 weeks postpartum, par-
ticipating women will be asked to provide:
 Non-clinical and clinical data.
 Blood and urine.
Women are not offered incentives to attend the follow
up visit, however, in The Gambia and Mozambique, if
needed, transport will be arranged to bring the woman
and her baby to the unit but no money is given.
Collection of samples (Tables 2, 3, and 4)
Blood Plasma samples will be used for placental growth
factor and nutritional status assessments. All samples
will be stored for later use in discovery science using
semi-agnostic proteomics, genomics, epigenomics and
metagenomics.
Cohort 1: We anticipate that each participant enrolled
in the non-pregnant cohort will provide one blood sam-
ple to the PRECISE Study at the time of enrolment. The
blood draw will be approximately 16 mL.
Cohort 2 We anticipate that each participant enrolled
in the pregnancy cohort will provide at least four blood
samples to the PRECISE Study: one at booking; one later
in pregnancy between 28+ 1–36+ 6 weeks’ gestation (at
least 4 weeks after the initial biological sampling); one
within 48 h postpartum and one at or after 6 weeks post-
partum. Each blood draw will be approximately 16 mL
(roughly equivalent to 1 tablespoon).
Cohorts 3 & 4 We anticipate that each participant en-
rolled in the pregnancy at ‘time-of-disease’ cohort will
provide from one to four blood samples to the PRECISE
study, depending upon when they present with compli-
cations: one at enrolment; and/or one later in pregnancy
between 28+ 1–36+ 6 weeks gestation (at least 4 weeks
after the initial biological sampling); one within 48 h
postpartum and one at or after 6 weeks postpartum.
Each blood draw will be approximately 16 mL (roughly
equivalent to 1 tablespoon).
All blood collection is intended to qualify as minimal
risk. The total volume and frequency, when considered
in the context of the clinical encounter, will not exceed
the following parameters (OHRP (45 CFR 46.110):
 For healthy, non-pregnant adults who weigh at least
50 kg, the amounts drawn may not exceed 550 mL
in an 8-week period and collection may not occur
more frequently than 2 times per week.
 For other adults and children, the amount drawn
may not exceed the lesser of 50 mL or 3 mL per kg
Table 2 Sampling from Cohort 1 (non-pregnant women of reproductive age)
Samples Enrolment
(Non-Pregnant)
Booking
(Pregnant)
Antenatal
(28+ 1–36+ 6)
Intra-partum Immediately
post-partum
Within 48 h
postpartum
Total
Collections
Blood 16 mL 1
Urine 20 mL 1
Vaginal swabs 4 swabs 1
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in an 8-week period and collection may not occur
more frequently than 2 times per week.
Cohort 5: We anticipate that participants enrolled in
the stillbirth cohort who are recruited postpartum will
provide two blood samples to the PRECISE Study: one
at enrolment and one at or after 6 weeks postpartum.
Each blood draw will be approximately 16 mL (roughly
equivalent to 1 tablespoon).
Urine Up to 20 mL of urine will be collected up to four
times, at the same time the blood sample is collected for
Cohorts 2, 3 and 4. For Cohort 1 (the Non-Pregnancy
Cohort), one urine sample will be collected once at the
time of enrolment. All samples will be stored for later
use in discovery science using semi-agnostic proteomics
and metagenomics.
Vaginal swabs With explicit additional consent, mid-
vaginal swabs will be collected at the booking visit and
when the women present to deliver. For Cohort 1 (the
Non-Pregnancy Cohort), vaginal swabs will be collected
once at the time of enrolment. For cohort 5, we will not
collect vaginal swabs. All samples will be stored for later
use, primarily related to metagenomics to gain insights
into the interaction between the vaginal microbiome and
pregnancy, newborn and puerperal outcomes.
Cord blood After delivery of the baby, the umbilical
cord is clamped and cut. The umbilical cord (including
the cord blood within it) is generally discarded along
with the placenta. After the cord is clamped and cut, the
cord blood will be collected. The amount of cord blood
drawn will be approximately 16 mL (roughly equivalent
to 1 tablespoon). All samples will be stored for later use
in discovery science using semi-agnostic proteomics,
genomics and epigenomics.
Placenta The placenta will be trimmed and weighed
and photographed using a digital camera in a fixed pos-
ition. Eight small coin-sized tissue samples will be taken
from the placenta, five 5 mm-long sections taken from
the cord and one strip of membrane. Four samples will
be processed in formalin for histology and the rest will
be flash frozen in liquid nitrogen for proteomic and
metabolomic analyses. All samples will be stored for
later use in discovery science correlating placental find-
ings with clinical outcomes and the outputs from the
‘omics science platforms.
Newborn blood Only if the cord blood collection is
missed, 2–3 drops of blood for DNA will be collected from
a heel stick prior to discharge from the facility. All samples
will be stored for later use in discovery science using semi-
agnostic proteomics, genomics and epigenomics.
Neonatal stool (Kenya only) The stool will be collected
to examine the newborn microbiome. The neonatal stool
sample will be collected from the baby’s nappy at the 6
weeks postpartum follow-up visit.
The samples will be collected, processed and stored in
adherence to the PRECISE Network biorepository stand-
ard operating procedures (SOPs) across all sites. Study
personnel at each site will receive initial and ongoing
training as needed to ensure SOPs are followed and
samples are of the highest quality.
Interactions with the clinical service
As PRECISE will improve the quality of antenatal care
provision, with accurate blood pressure measurement, a
focus on stillbirth, and routine pulse oximetry, the re-
search team recognises that defined clinical responses
are incumbent on us, primarily through referral into
existing clinical pathways. We are determining if and
how to add mental health elements to the protocol
Table 3 Sampling from Cohort 2 (unselected pregnant women) and Cohorts 3 & 4 (women at time-of-disease) and their infants
Samples Booking Antenatal Intra-
partum
Immediately postpartum Within 48 h postpartum 6 weeks
postpartum
Total
Collections
Blood 16mL 16 mL 16 mL 16 mL 4
Urine 20mL 20 mL 20 mL 20 mL 4
Vaginal
swabs
4 swabs 4 swabs 2
Cord
blood
16 mL 1
Placental
tissue
14 small pieces of tissue,
membrane and cord
1
Newborn
blood
2–3 drops from heel stick ONLY if cord
blood is not collected
1
Neonatal
stool
Approximately
100 mg
1a
aCohorts 2 and 3 in Kenya only
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through qualitative research. An important piece of prior
work is to identify the clinical pathways for women iden-
tified with mental health emergencies.
Co-ordination
Academic co-ordination and general oversight are shared
between the central PRECISE teams located at KCL and
UBC. In-country clinical co-ordination is supplied by the
research teams located in Farafenni (The Gambia), Mom-
basa (Kenya) and Manhiça (Mozambique), with central
support in Fajara and Nairobi, in The Gambia and Kenya,
respectively. Details of the monitoring and quality assur-
ance plans are included in the database and biorepository
papers (Craik R, et al.: Baobab Laboratory Information
Management System, submitted).
Statistical approach
Our two principal analytical approaches will be to iden-
tify factors that predict the onset of placental disorders
and factors that identify women, fetuses and newborns
at incrementally increased risk at time-of-disease with
pregnancy hypertension and FGR. We will prioritise
modifiable factors to accelerate clinical improvements.
The detailed statistical plan is being developed and will
be published in due course.
Discussion
This protocol paper summarises the clinical aspects of
the PRECISE Network’s field activities and, as stated,
should be read alongside the database and biobanking
papers for a full understanding of the scope and detail of
what is now underway in The Gambia, Kenya, and
Mozambique.
To accelerate progress towards the women’s and chil-
dren’s health-relevant Sustainable Development Goals,
we need to understand how a variety of social, chronic
disease, biomarker and pregnancy-specific determinants
health interact to result in either a resilient or a compro-
mised pregnancy for either mother or fetus/newborn, or
both. It is our opinion that this protocol has been de-
signed to create such a depth of understanding.
We are seeking funding to maintain the cohort to bet-
ter understand the implications of pregnancy complica-
tions for both maternal and child health, as well as
additional funds to begin intervention studies (e.g.,
stepped-wedge cluster randomised controlled trials) to
convert what we already know and what has been learnt
from PRECISE into clinical care in the communities that
have dedicated themselves to a shared PRECISE vision
and agenda.
Our findings will be of interest to the women and their
communities, the local and national health systems, sci-
entific colleagues, health advocates and funders. We
have developed a comprehensive and multi-layered com-
munications strategy to reach out to each of these
groups, whether through direct oral interactions, info-
graphics, presentations at scientific (e.g., Society for Re-
productive Investigation) or advocacy (e.g., Women
Deliver) meetings, policy briefs and scientific papers. By
embedding our advocacy and engagement within gov-
ernments, multilaterals and NGOs, we envision local im-
plementation of interventions demonstrated through the
PRECISE study to be robust and effective reducing ma-
ternal and neonatal mortality and morbidity.
Conclusion
The name for PRECISE implies a commitment to preci-
sion medicine, and this protocol has the potential to lead
to the provision of individualised, precision health care
to women and their infants whether they encounter the
health system on their doorsteps or at the tertiary refer-
ral hospital.
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